Uveitis after the bnt162b2 mrna vaccination against sars-cov-2 infection

Tamar Rabinovitch, Yael Ben-Arie-Weintrob, Tamar Hareuveni-Blum, Boaz Shaer, Vicktoria Vishnevskia-Dai, Shiri Shulman, Hadas Newman, Muhammad Biadsy, Dua Masarwa, Naomi Fischer, Oren Yovel, Shalhevet Goldfeather-Ben Zaken, Zohar Habot-Wilner*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

89 Scopus citations

Abstract

Purpose: To describe uveitis cases after the BNT162b2 mRNA SARS-CoV-2 vaccination. Methods: This is a multicenter, retrospective study. Vaccine-related uveitis diagnosis was supported by the classification of the World Health Organization Adverse Drug Terminology and the Naranjo criteria. Results: Twenty-one patients (23 eyes) with a mean age of 51.3 years (23-78 years) were included. Eight of the 21 patients had a known history of uveitis. The median time from previous to current attack was 1 year (0.5-15 years). There were 21 anterior uveitis cases, two with bilateral inflammation. Eight cases occurred after the first vaccination and 13 after the second vaccination. All but three presented as mild to moderate disease. Two patients developed multiple evanescent white dot syndrome after the second vaccination. The mean time from vaccination to uveitis onset was 7.5 ± 7.3 days (1-30 days). At final follow-up, complete resolution was achieved in all but two eyes, which showed significant improvement. One case of severe anterior uveitis developed vitritis and macular edema after the second vaccination, which completely resolved after an intravitreal dexamethasone injection. Conclusion: Uveitis may develop after the administration of the BNT162b2 mRNA vaccine. The most common complication was mild to moderate anterior uveitis, while multiple evanescent white dot syndrome can also occur less frequently.

Original languageEnglish
Pages (from-to)2462-2471
Number of pages10
JournalRetina
Volume41
Issue number12
DOIs
StatePublished - 1 Dec 2021

Keywords

  • BNT162b2 mRNA SARS-CoV-2 vaccination
  • BNT162b2 mRNA vaccine
  • COVID- 19
  • Drug-induced uveitis
  • MRNA vaccine
  • Pfizer-BioNTech COVID-19 vaccine
  • Uveitis
  • Vaccine- associated uveitis
  • Vaccine-induced uveitis

Fingerprint

Dive into the research topics of 'Uveitis after the bnt162b2 mrna vaccination against sars-cov-2 infection'. Together they form a unique fingerprint.

Cite this